Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 67.00 | |
5 mg | In stock | $ 163.00 | |
10 mg | In stock | $ 247.00 | |
25 mg | In stock | $ 472.00 | |
50 mg | In stock | $ 693.00 | |
100 mg | In stock | $ 988.00 | |
500 mg | In stock | $ 1,980.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 166.00 |
Description | NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM). |
Targets&IC50 | CDK7-CyclinH-MAT1:3564 nM, CDK1-CyclinB:2 nM, CDK9-CyclinT1:15 nM, CDK2-CyclinE:5 nM, CDK3-CyclinE:42 nM, CDK5-p25:1 nM, CDK2-CyclinA:2 nM, CDK5-p35:1 nM, CDK6-CyclinD3:187 nM |
In vitro | NVP-LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-1 mol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. In MM cells, LCQ195 triggered decreased amplitude of transcriptional signatures associated with oncogenesis, drug resistance and stem cell renewal, including signatures of activation of key transcription factors for MM cells e.g. myc, HIF-1a, IRF4[1]. |
In vivo | Bortezomib-treated MM patients whose tumours had high baseline expression of genes suppressed by LCQ195 had significantly shorter progression-free and overall survival than those with low levels of these transcripts in their MM cells[1]. |
Synonyms | AT9311, LCQ-195 |
Molecular Weight | 460.33 |
Formula | C17H19Cl2N5O4S |
CAS No. | 902156-99-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (217.24 mM)
H2O: Insoluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NVP-LCQ195 902156-99-4 Cell Cycle/Checkpoint CDK NVPLCQ195 AT9311 AT-9311 inhibit Cyclin dependent kinase Inhibitor NVP LCQ195 LCQ 195 LCQ-195 NVP-LCQ-195 LCQ195 AT 9311 NVP-LCQ 195 inhibitor